GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oryzon Genomics SA (XMAD:ORY) » Definitions » EV-to-Revenue

Oryzon Genomics (XMAD:ORY) EV-to-Revenue : (As of Jun. 04, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Oryzon Genomics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Oryzon Genomics's enterprise value is €128.00 Mil. Oryzon Genomics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil. Therefore, Oryzon Genomics's EV-to-Revenue for today is .

The historical rank and industry rank for Oryzon Genomics's EV-to-Revenue or its related term are showing as below:

During the past 10 years, the highest EV-to-Revenue of Oryzon Genomics was 7819.19. The lowest was 13.82. And the median was 3650.20.

XMAD:ORY's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.075
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-04), Oryzon Genomics's stock price is €2.00. Oryzon Genomics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00. Therefore, Oryzon Genomics's PS Ratio for today is .


Oryzon Genomics EV-to-Revenue Historical Data

The historical data trend for Oryzon Genomics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oryzon Genomics EV-to-Revenue Chart

Oryzon Genomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oryzon Genomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oryzon Genomics's EV-to-Revenue

For the Biotechnology subindustry, Oryzon Genomics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oryzon Genomics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oryzon Genomics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Oryzon Genomics's EV-to-Revenue falls into.



Oryzon Genomics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Oryzon Genomics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=128.004/0
=

Oryzon Genomics's current Enterprise Value is €128.00 Mil.
Oryzon Genomics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oryzon Genomics  (XMAD:ORY) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Oryzon Genomics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=2.00/0
=

Oryzon Genomics's share price for today is €2.00.
Oryzon Genomics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oryzon Genomics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Oryzon Genomics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Oryzon Genomics (XMAD:ORY) Business Description

Traded in Other Exchanges
Address
Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.

Oryzon Genomics (XMAD:ORY) Headlines

No Headlines